Manal F. Abdelmalek, MD

Professor of Medicine
Campus mail 03119 Hosp South, Suite 03107, Room 03125, Durham, NC 27710
Phone (919) 684-3262
Email address manal.abdelmalek@duke.edu

My research interests include metabolic liver disease, particularly obesity-related liver disease and its association with complications of the insulin resistance syndrome. I am interested in studying the clinical, environmental, and genetic risk factors for nonalcoholic fatty liver disease, new therapeutic options for treatment, and evaluating the impact of NAFLD from a public health perspective.

In Their Words

Education and Training

  • Fellow in Gastroenterology, Medicine, Mayo School of Health Sciences, 1995 - 1998
  • Medical Resident, Medicine, Mayo School of Health Sciences, 1992 - 1995
  • M.D., University Missouri Kansas City, 1992

Publications

Jensen, T, Abdelmalek, MF, Sullivan, S, Nadeau, KJ, Green, M, Roncal, C, Nakagawa, T, Kuwabara, M, Sato, Y, Kang, D-H, Tolan, DR, Sanchez-Lozada, LG, Rosen, HR, Lanaspa, MA, Diehl, AM, and Johnson, RJ. "Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. (Accepted)" Journal of hepatology 68, no. 5 (May 2018): 1063-1075. (Review)

PMID
29408694
Full Text

Harrison, SA, Rinella, ME, Abdelmalek, MF, Trotter, JF, Paredes, AH, Arnold, HL, Kugelmas, M, Bashir, MR, Jaros, MJ, Ling, L, Rossi, SJ, DePaoli, AM, and Loomba, R. "NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial." Lancet (London, England) (March 5, 2018).

PMID
29519502
Full Text

Vuppalanchi, R, Siddiqui, MS, Van Natta, ML, Hallinan, E, Brandman, D, Kowdley, K, Neuschwander-Tetri, BA, Loomba, R, Dasarathy, S, Abdelmalek, M, Doo, E, Tonascia, JA, Kleiner, DE, Sanyal, AJ, Chalasani, N, and NASH Clinical Research Network, . "Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease." Hepatology (Baltimore, Md.) 67, no. 1 (January 2018): 134-144.

PMID
28859228
Full Text

Younossi, ZM, Loomba, R, Rinella, ME, Bugianesi, E, Marchesini, G, Neuschwander-Tetri, BA, Serfaty, L, Negro, F, Caldwell, SH, Ratziu, V, Corey, KE, Friedman, SL, Abdelmalek, MF, Harrison, SA, Sanyal, AJ, Lavine, JE, Mathurin, P, Charlton, MR, Chalasani, NP, Anstee, QM, Kowdley, KV, George, J, Goodman, ZD, and Lindor, K. "Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)." Hepatology (Baltimore, Md.) (December 9, 2017). (Review)

PMID
29222911
Full Text

Younossi, ZM, Loomba, R, Anstee, QM, Rinella, ME, Bugianesi, E, Marchesini, G, Neuschwander-Tetri, BA, Serfaty, L, Negro, F, Caldwell, SH, Ratziu, V, Corey, KE, Friedman, SL, Abdelmalek, MF, Harrison, SA, Sanyal, AJ, Lavine, JE, Mathurin, P, Charlton, MR, Goodman, ZD, Chalasani, NP, Kowdley, KV, George, J, and Lindor, K. "Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis." Hepatology (Baltimore, Md.) (December 9, 2017). (Review)

PMID
29222917
Full Text

Shadab Siddiqui, M, Harrison, SA, Abdelmalek, MF, Anstee, QM, Bedossa, P, Castera, L, Dimick-Santos, L, Friedman, S, Greene, K, Kleiner, D, Megnien, S, Neuschwander-Tetri, BA, Ratziu, V, Schabel, E, Miller, V, Sanyal, AJ, and Liver Forum Case Definitions Working Group, . "Case definitions for inclusion and analysis of endpoints in clinical trials for NASH through the lens of regulatory science." Hepatology (Baltimore, Md.) (October 23, 2017).

PMID
29059456
Full Text

Wegermann, K, Moylan, CA, Zheng, J, Abdelmalek, MF, Chow, S-C, Guy, CD, Diehl, AM, and Suzuki, A. "Gender and menopause significantly modify effects of metabolism-related SNPs on fibrosis stage in adult patients with nonalcoholic fatty liver disease (NAFLD)." October 2017.

Scholars@Duke

Harrison, SA, Abdelmalek, MF, Diehl, AM, Caldwell, S, Shiffman, ML, Ghalib, R, Lawitz, E, Rockey, DC, Schall, REA, Jia, C, McColgan, BJ, Myers, RP, Subramanian, M, McHutchison, JG, Muir, AJ, Ratziu, V, Afdhal, NH, Goodman, ZD, Bosch, J, and Sanyal, AJ. "Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis." October 2017.

Scholars@Duke

Younossi, ZM, Stepanova, M, Sanyal, AJ, Harrison, SA, Ratziu, V, McColgan, BJ, Myers, RP, Subramanian, M, McHutchison, JG, Afdhal, NH, Abdelmalek, MF, Bosch, J, and Goodman, ZD. "Predictors of Fibrosis Progression and Regression by Histology and Morphometrically Quantified Collagen in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis." October 2017.

Scholars@Duke

Abdelmalek, MF, Thompson, M, Gathe, JC, Lefebvre, E, Seyedkazemi, S, Utay, NS, and Francque, S. "Favorable safety and tolerability of the dual CCR2/5 antagonist cenicriviroc in over 1000 subjects treated to date." October 2017.

Scholars@Duke

Pages